Silexan in the Treatment Of Posttraumatic Stress Disorder Trial

Recruiting Phase 3 Interventional Study
Post Traumatic Stress Disorder
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
278 (estimated)
Sponsor
Deakin University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Posttraumatic stress disorder (PTSD) is a common and debilitating mental illness. Current treatments for PTSD include psychotherapy and antidepressant medications. Many patients are unable to tolerate psychotherapy for PTSD and drop out of it. In addition, its effectiveness is limited. Up to 50 percent of patients who receive psychotherapy do not benefit from it. Antidepressant medications have on…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Aged 18 years or over. 2. Fluent in English. 3. Meet DSM-5 criteria for PTSD, irrespective of occupation (e.g. first responder, police officer, ex-military or civilian), determined using the Mini International Neuropsychiatric Interview 7.0.2. 4. Have a score on the PTSD Chec…
Contacts

Greg Roebuck, MD

+61 3 9035 4749

greg.roebuck@unimelb.edu.au

CONTACT

Georgia Parkin, PhD

+61 3 9035 3417

georgia.parkin@unimelb.edu.au

CONTACT